Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ross Products

This article was originally published in The Tan Sheet

Executive Summary

Similac and Ensure marketer's U.S. sales up 1% to $493 mil. in Q4 and 4% to $2.03 bil. for the year. Abbott Labs division reports growth in pediatric nutritionals continues to be driven by new products, line extensions and innovative packaging; Ross recently began rolling out to selected markets Isomil Soy Formula with Iron in "ready-to-feed" aseptic bottles and also launched Similac 2 with Iron in infant and toddler formulas. Abbott's overall fourth quarter net sales increased 6.8% to $3.7 bil. as net earnings jumped 13.5% to $753.4 mil. For the year, net sales reached $13.75 bil., up 4.3%, and net earnings saw a 13.9% spike to $2.79 bil
Advertisement

Related Content

Coupon Accounting Adjustment Revenue Impact Cited To Analysts
Coupon Accounting Adjustment Revenue Impact Cited To Analysts
Coupon Accounting Adjustment Revenue Impact Cited To Analysts

Topics

Advertisement
UsernamePublicRestriction

Register

PS092132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel